Novelon 0.15/0.: Compound Profile
Novelon 0.15/0.03 mg MSD is a combination pharmaceutical preparation containing desogestrel (0.15 mg) and ethinylestradiol (0.03 mg) manufactured by Merck Sharp & Dohme. This dual-hormone formulation represents a third-generation oral contraceptive compound widely studied in reproductive endocrinology and hormonal biochemistry research. Researchers investigating contraceptive mechanisms, hormonal interactions, and reproductive physiology frequently examine this specific combination for its distinct pharmacological profile. Laboratory studies focus on the synthetic progestin desogestrel’s selective receptor binding characteristics and its interaction with the synthetic estrogen component. The compound serves as a valuable reference standard for comparative studies of hormonal contraceptive formulations and their metabolic pathways in cellular research models.
Laboratory Applications
Research institutions examine Novelon formulations to investigate hormonal feedback mechanisms, endocrine disruption pathways, and contraceptive efficacy models in controlled laboratory environments. The desogestrel component demonstrates high oral bioavailability and minimal androgenic activity in preclinical studies, making it suitable for comparative receptor binding assays. Scientists studying reproductive hormone interactions analyse this combination to understand ovarian suppression mechanisms and hypothalamic-pituitary-gonadal axis modulation. Biochemistry laboratories investigate the compound’s effects on sex hormone-binding globulin levels and lipid metabolism markers. Researchers at Stroid UK Shop and similar facilities studying other drugs find this formulation valuable for endocrine research protocols. Studies often compare this combination with SARMs and peptides in hormonal pathway research to understand selective receptor modulation mechanisms and tissue-specific responses in laboratory settings.
Technical Specifications
| Parameter | Value |
|---|---|
| Active Components | Desogestrel 0.15mg + Ethinylestradiol 0.03mg |
| Manufacturer | MSD (Merck Sharp & Dohme) |
| Formulation | Oral tablet |
| Desogestrel CAS | 54024-22-5 |
| Ethinylestradiol CAS | 57-63-6 |
| Storage Conditions | Room temperature, dry environment |
| Research Grade | Pharmaceutical standard |
Research Compliance
This product is supplied exclusively for in-vitro research and analytical reference purposes. Novelon 0.15/0.03 mg MSD is intended for qualified researchers studying reproductive endocrinology, contraceptive mechanisms, and hormonal biochemistry in laboratory settings. This compound is not intended for human consumption, clinical trials, or therapeutic applications. Researchers must ensure appropriate institutional approvals and safety protocols are in place before conducting studies with this pharmaceutical reference material.
